The role of leukotriene modifiers in the treatment of asthma.
Horwitz
R J
RJ
Department of Medicine, University of Wisconsin Hospital and Clinics, Madison 53792, USA.
McGill
K A
KA
Busse
W W
WW
D000818:Animals; D001249:Asthma / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D007211:Indoles; D020024:Leukotriene Antagonists; D015289:Leukotrienes / Q000502:physiology; D016859:Lipoxygenase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D048448:Phenylcarbamates; D013449:Sulfonamides; D014105:Tosyl Compounds / Q000009:adverse effects / Q000627:therapeutic use
D007211:Indoles; D020024:Leukotriene Antagonists; D015289:Leukotrienes; D016859:Lipoxygenase Inhibitors; D048448:Phenylcarbamates; D013449:Sulfonamides; D014105:Tosyl Compounds; C063449:zileuton; D006918:Hydroxyurea; C062735:zafirlukast